Flurbiprofen Axetil
PreclinicalSmall molecule
Flurbiprofen Axetil is one of 20 small molecule programs targeting Enhanced Recovery After Surgery. It is currently in Preclinical.
2
Indications
9
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Analgesia
#DrugCompanyPhaseTrials
1Sufenta
LLeaf Vertical Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Penthrane
PPurdue Pharma, Canada
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Oxycontin
PPurdue Pharma LP
Phase 3
Intrathecal Morphine
Pacira Pharmaceuticals, IncPhase 3
Esketamine Combined With Dexmedetomidine
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Marcaine
IInnocoll
Phase 1
Narcan
SScienture
Phase 1
Kenalog
BBassett Healthcare
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lung Cancer2 trials
Enhanced Recovery After Surgery1 trial
The Effect of Enhanced Recovery After Surgery in Endoscopic Sinus Surgery
Completed·—·N/A·NCT04048070·55 enrolled
Hyperalgesia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Flurbiprofen Axetil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University